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Objective: This study compares two different negative pressure wound ther-
apy (NPWT) modalities in the treatment of venous leg ulcers (VLUs), the
ultraportable mechanically powered (MP) Smart Negative Pressure (SNaP)
Wound Care System to the electrically powered (EP) Vacuum-Assisted Closure
(V.A.C.) System.
Approach: Patients with VLUs from 13 centers participated in this prospec-
tive randomized controlled trial. Each subject was randomly assigned to
treatment with either MP NPWT or EP NPWT and evaluated for 16 weeks or
complete wound closure.
Results: Forty patients (n = 19 MP NPWT and n = 21 EP NPWT) completed the
study. Primary endpoint analysis of wound size reduction found wounds in the
MP NPWT group had significantly greater wound size reduction than those in
the EP NPWT group at 4, 8, 12, and 16 weeks ( p-value = 0.0039, 0.0086,
0.0002, and 0.0005, respectively). Kaplan–Meier analyses showed greater ac-
celeration in complete wound closure in the MP NPWT group. At 30 days, 50%
wound closure was achieved in 52.6% (10/19) of patients treated with MP
NPWT and 23.8% (5/21) of patients treated with EP NPWT. At 90 days,
complete wound closure was achieved in 57.9% (11/19) of patients treated with
MP NPWT and 38.15% (8/21) of patients treated with EP NPWT.
Innovation: These data support the use of MP-NPWT for the treatment of
VLUs.
Conclusions: In this group of venous ulcers, wounds treated with MP NPWT
demonstrated greater improvement and a higher likelihood of complete wound
closure than those treated with EP NPWT.
INTRODUCTION
Venous leg ulcers (VLUs) con-
stitute a significant healthcare prob-
lem due to impaired healing.1,2 VLUs
usually result in substantial dis-
ability, reduced quality of life, and
high economic costs.3–13 Effective
treatment of VLUs involves the use
of compression therapy to address
the underlying venous disease and
adjuncts such as advanced cellular
and acellular wound care matrices
(e.g., Apligraf, Organogenesis, Inc,
Canton, MA; Oasis, Cook Biotech,
Inc, West Lafayette, IN). Negative
pressure wound therapy (NPWT) has
been shown to create a moist wound
healing environment, drain exudate,
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reduce tissue edema, mechanically stimulate the
wound bed, and augment blood perfusion at the
wound edge thereby enhancing angiogenesis and
formation of granulation tissue to reduce healing
time.14 The primary treatment goal of NPWT, the
topical application of subatmospheric pressure to
a wound bed through a specialized dressing is
wound closure, with the secondary goals of reduc-
ing wound dimensions and improving the quality of
the wound bed.15
NPWT is traditionally delivered by an electri-
cally powered (EP) pump, such as the widely used
Vacuum-Assisted Closure (V.A.C.) Therapy Sys-
tem (K.C.I., San Antonio, TX), which was the first
commercially available NPWT system and remains
the most widely used and studied NPWT system on
the market today. EP NPWT systems are usually
larger in size and have the ability to provide
varying therapy (continuous and intermittent),
and thus they are best suited for treating larger,
more complex wounds. However, EP NPWT sys-
tems have several disadvantages in the outpatient
setting because of their weight and bulk, need for
an electrical power source, difficult rental-based
procurement process, high cost, and negative im-
pact on patient mobility and quality of life. Since
most venous ulcers are treated in the outpatient
setting, this has resulted in limited use of NPWT on
VLUs in general though significant evidence sup-
ports the benefit of NPWT for VLUSs healing.14–23
Recently, a single use, mechanically powered
(MP) NPWT system has been developed called the
Smart Negative Pressure (SNaP) Wound Care
System (Spiracur, Inc., Sunnyvale, CA).24 Instead
of using an electric pump to generate negative
pressure, the MP device utilizes specialized springs
to generate a preset continuous subatmospheric
pressure level to the wound bed. By eliminating the
electric pump, this device helps solve many of the
constraints associated with traditional NPWT use
in the ambulatory setting. Previous studies have
shown that negative pressure delivered by the MP
NPWT device has characteristics similar to the EP
NPWT system in both biomechanical testing and in
an animal wound healing model.25 Most recently, a
study comparing MP NPWT-treated patients to
modern treatment protocols for highly refractory
lower extremity ulcers demonstrated time to heal-
ing improvements similar to studies using EP
NPWT devices.19 Importantly, the MP NPWT sys-
tem has indications from the FDA for the treat-
ment of VLUs.
This study is a sub-analysis of a previously
published prospective, multicenter, randomized
controlled study of 132 patients with lower ex-
tremity wounds that included a large sample of
VLUs.17 This study directly compares the MP
NPWT system to the EP NPWT system for the
treatment of venous ulcers. We hypothesized
equivalent outcomes between the two NPWT sys-
tems in the treatment of venous ulcers in the lower
extremity.
CLINICAL PROBLEM ADDRESSED
VLUs represent a significant challenge for wound
care professionals due to their delayed healing and
poor wound bed characteristics. NPWT has been
shown to be effective in improving healing of VLUs,
but traditional EP NPWT has been challenging to
implement in the outpatient care setting.14–23 This
study provides insight into the newer MP NPWT
modality that allows for the practical treatment of
these wounds in the outpatient setting.
MATERIALS AND METHODS
This was a multicenter, prospective, randomized
controlled clinical trial designed to evaluate the rel-
ative impact on wound closure using a MP NPWT
system (SNaP Wound Care System; Spiracur, Inc.,
Sunnyvale, CA) versus an EP NPWT system (V.A.C.
Therapy System; KCI). This study was conducted in
compliance with the 1975 Declaration of Helsinki
and under presiding institutional review board ap-
proval. The study was registered at clinicaltrials.gov
under number: NCT00951080. Subjects were re-
cruited from 13 sites in the United States, with a
mixture of physician offices, and private and aca-
demic wound care centers. Subjects were evaluated
on a weekly basis to complete wound closure (defined
as complete reepithelialization without drainage) or
for up to 16 weeks of therapy. Dressing changes were
performed following instructions recommended by
manufacturer. For all enrolled subjects, debride-
ment was performed in the wound care clinic as part
of the normal standard of care (maximum 1 · /week).
Wound sizes were evaluated using wound tracings
captured by the Visitrak wound measurement sys-
tem (Smith & Nephew, Hull, England).
Inclusion criteria for the full study, included
patients aged ‡ 18 years; lower extremity VLUs or
diabetic ulcer with a surface area < 100 cm2 but
larger than 1 cm2, and < 10 cm in widest diameter.
Wounds were to have been present for > 30 days
despite appropriate wound care prior to admission.
Admission criteria also required adequate blood
perfusion defined as transcutaneous oxygen mea-
surements of the dorsum of the foot > 30 mmHg,
skin perfusion pressure > 30 mmHg, or an ankle/
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brachial index between 0.7 and 1.2. The wound was
required to be in a location amenable to creation of
an airtight seal using the provided dressings.
Exclusion criteria included active infection (red-
ness, swelling, pain, and purulent exudate), un-
treated osteomyelitis, pregnancy, allergies to wound
care products used in the study, etiologies of the
wound that included malignancy, burn, collagen
vascular disease, sickle cell, vasculopathy, or pyo-
derma gangrenosum. Further grounds for exclusion
included a diagnosis of active Charcot arthropathy,
wound location on toes or plantar surface of foot,
end-stage renal disease requiring dialysis, active
chemotherapy treatment, previous treatment with a
NPWT device, growth factors, hyperbaric oxygen, or
bioengineered tissue product within 30 days of en-
rollment. Patients were not enrolled if they exhibited
greater than 30% wound surface area reduction in
size at 1 week after the screening visit.
Randomization
Randomization was accomplished using blocks
of numbers from Pocock.26 Stratification was per-
formed by treatment center. Sealed opaque enve-
lopes contained the assigned treatment and patient
identification number. Envelopes were sequentially
numbered before clinical trial site distribution. At
patient randomization, treatment was assigned on
the basis of the next sequentially labeled envelope.
Blinding
Evaluation of the Visitrak tracing was per-
formed in a blinded fashion. However, subject and
investigator blinding could not be performed based
on the differences in device appearance.
Statistical analysis
The sub-analysis of the venous ulcers mirrored
the analysis of the overall intent to treat (ITT) pop-
ulation.17 VLUs were defined as those patients who
had a leg ulcer in the gaiter region with evidence of
venous disease on physical exam and were not dia-
betic. Patient demographics and comorbidities were
compared across device type using standard t-tests
for continuous variables and Fisher’s exact test for
categorical variables. Percent wound reduction was
measured at 4, 8, 12, and 16 weeks. If a wound was
completely healed or a subject had discontinued
prior to completion of 16 weeks, the last observation
was carried forward for the intent-to-treat analysis.
Wound reduction at each time point was compared
between the two device groups using the nonpara-
metric Wilcoxon Rank Sum test. This nonparamet-
ric test was used because a Shapiro–Wilk test
indicated non-normality of the data at each time
point. The comparison of percent wound reduction
was repeated using rank transformed data in a lin-
ear model to adjust for baseline wound areas.
Finally, a Kaplan–Meier and Life Table analysis
were performed to compare the time (in days) to
healing between the two device groups. Additionally,
since these devices were used as a monotherapy, we
also compared the surrogate marker of 50% wound
closure rate at 30 days to allow us to predict the
intended clinical endpoint of wound healing.27,28 The
thirty-day timeframe is also important because this
considered the cutoff point for evaluating the effec-
tiveness of a therapy on wound progression in many
studies. Primary healing analysis was performed on
the Visitrak data and the reported wound closure
outcomes. Statistical analyses were performed using
SAS version 9.1.
Secondary outcome analysis
Serious adverse events, device-related adverse
events, and complications were also collected and
reported.
RESULTS
This analysis involved 40 patients (n = 19 MP
NPWT, n = 21 EP NPWT) who completed the
study with either healing or 16 weeks of therapy.
Overall, the average age was 67 years and 52% of
patients were women. Fifteen percent of patients
were smokers and 12.5% had coexistent mild to
moderate peripheral artery disease. There were no
significant differences in the baseline demograph-
ics comparing the MP NPWT group to the EP
NPWT group (Table 1).
Despite randomization, there were differences
in the mean initial wound size (mean – SD: 4.85 –
4.49 cm2 for MP NPWT versus 11.60 – 12.12 cm2 for
Table 1. Pure venous leg ulcer comorbid demographics
Demographic V.A.C. SNaP  p-Value
Age (mean – SD, years) 66.8 – 18.1 (21) 67.5 – 14.8 (19) 0.9045
Male (%) 52.4% (11/21) 42.1% (8/19) 0.5450
Race (% white) 76.2% (16/21) 89.5% (17/19) 0.4124
Current smoker (%) 9.5% (2/21) 21.1% (4/19) 0.3976
Lower extremity edema (%) 76.2% (16/21) 68.4% (13/19) 0.7271
PAD (%) 14.3% (3/21) 10.5% (2/19) 1.0000
Peripheral neuropathy (%) 19.0% (4/21) 5.3% (1/19) 0.3451
COPD/asthma (%) 9.5% (2/21) 5.3% (1/19) 1.0000
Cardiac disease (%) 47.6% (10/21) 42.1% (8/19) 0.7605
Anticoagulated/coumadin (%) 33.3% (7/21) 36.8% (7/19) 1.0000
Immobility (%) 23.8% (5/21) 26.3% (5/19) 1.0000
Steroid use (%) 4.8% (1/21) 5.3% (1/19) 1.0000
Poor nutrition (%) 4.8% (1/21) 10.5% (2/19) 0.5962
Other comorbidity (%) 4.8% (1/21) 5.3% (1.19) 1.0000
PAD, peripheral artery disease; SNaP, Smart Negative Pressure; V.A.C.,
Vacuum-Assisted Closure.
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EP NPWT). For all 40 patients treated with NPWT,
22.5% (9/40) of the wounds were closed at 8 weeks
and 52.5% (21/40) were closed after 16 weeks of
treatment. The average% decrease in wound area
was 38.4% at 8 weeks and 49.5% at 16 weeks.
Comparison of VLUs treatment with EP NPWT
versus MP NPWT
The incidence of complete wound closure over time
is represented for each group by Kaplan–Meier esti-
mates in Fig. 1. Although there is a trend toward
superior overall wound closure in the MP group,
there was no significant difference (p = 0.3547 with-
out or with ( p = 0.4656) adjustment for baseline
wound size) in the proportion of subjects that com-
pletely healed over time. Based on the surrogate
endpoint of 50% wound closure, 52.63% (10/19) of MP
NPWT subjects versus 23.8% (5/21) of EP NPWT
subjects experienced 50% wound closure at 30 days;
odds ratio was 3.56 with a 95% confidence interval
(CI) of [0.923, 13.699]. Hence, EP NPWT treated pa-
tients were 3.5 times more likely not to have achieved
50% wound closure at 30 days. However, ad hoc
analysis at 90 days showed that the proportion of MP
NPWT patients healed was 57.9% (11/19) compared
with 38.15 (8/21) for the EP NPWT (odds ratio esti-
mate: 2.23 with a 95% CI of [0.63, 7.93]). Hence, at 90
days, patients treated with the EP NPWT device were
twice more likely not to have healed than patients
treated with the MP NPWT device.
The percent decrease in wound area as measured
from Visitrak tracings was compared for those sub-
jects randomized to either treatment with the MP
NPWT System or the EP NPWT System. The Sha-
piro–Wilk test indicated significant variation from a
normal distribution ( p < 0.0001) in the data for each
interval and as such, the primary endpoint was
evaluated using nonparametric methods. A Wilcox-
on Rank Sum Test was conducted and the results
indicated that the MP NPWT-treated subjects ex-
perienced significantly greater percent wound clo-
sure than EP NPWT-treated subjects at 4, 8, 12, and
16 weeks ( p-value = 0.0039, 0.0086, 0.0002, and
0.0005, respectively). The mean percent decrease in
wound area is provided along with the results from
the Wilcoxon Sum Rank Test in Table 2. To evaluate
how patients responded if they completed the pre-
scribed treatment, the data were analyzed based on
those subjects who completed the entire study pro-
tocol (either healed or had follow-up data through 16
weeks of treatment). Given the difference in baseline
wound size between the treatment groups, covariate
analysis was performed to see whether wound size
affected the statistical significance. We found the
Figure 1. Kaplan–Meier graph showing time to healing; NPWT (SNaP System and V.A.C. Therapy System) effective at treating venous leg ulcers. NPWT,
negative pressure wound therapy; SNaP, Smart Negative Pressure; V.A.C., Vacuum-Assisted Closure. To see this illustration in color, the reader is referred to
the web version of this article at www.liebertpub.com/wound
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difference in baseline wound size statistically im-
pacted the wound size reduction results at 8 and 12
weeks ( p-value = 0.0419 and 0.0470, respectively).
After adjusting for baseline wound size, significant
differences in the percentage of wound closure be-
tween groups was maintained at 4, 12, and 16 weeks
( p-value = 0.0346, 0.0079, and 0.0082, respectively),
as shown in Table 2.
Adverse events and incidence of infection
Device-related adverse events and complications
such as infection were similar between treatment
groups (Table 3) and was consistent with the larger
population previously reported.17
DISCUSSION
NPWT is a well-characterized method of therapy
for chronic nonhealing ulcers.29–31 Though there is
significant reason for the potential benefits of NPWT
for the treatment of VLUs, there is only one venous
ulcer-specific randomized controlled trial (RCT) uti-
lizing NPWT.23 However, several other RCTs that
include VLUs patients have demonstrated superior
healing with NPWT.15–17,23,32–34 In addition to RCT
data, there have been a number of retrospective
comparison studies and case series that have dem-
onstrated excellent results using NPWT for the
treatment of refractory venous ulcers.14,19 Vuerstaek
et al. reported a randomized study of NPWT for the
treatment of venous ulcers enrolling 60 patients. In
their study, they concluded that compared to con-
ventional wound care, EP NPWT should be consid-
ered the treatment of choice for chronic leg ulcers
owing to its significant advantage in time to complete
wound healing (29 days vs. 45 days for EP NPWT
and conventional therapy, respectively, p = 0.0001),
and especially time to wound bed preparation (7 days
vs. 17 days for EP NPWT and conventional therapy,
respectively, p = 0.05), and lower cost ($3,881 vs.
$5,452 for EP NPWT and conventional therapy, re-
spectively, p = 0.001).23 In a retrospective analysis,
Yao et al. showed that patients treated with NPWT
healed faster even when they had significantly
greater comorbidities, and that early intervention
with NPWT demonstrated better healing.14 Using
real world data, they found that venous ulcers trea-
ted with NPWT were 6.31 times more likely to heal
than those ulcers treated with conventional therapy.
In this article we present a subgroup analysis
of a previously reported prospective randomized
study comparing MP NPWT to EP NPWT. Overall,
NPWT as a monotherapy was able to heal 52.5% of
VLUs at 16 weeks of treatment. However, the data
demonstrated that wound size reduction was sig-
nificantly faster in the MP NPWT group compared
with the EP NPWT group and that there was a
trend toward overall greater healing in the MP
NPWT group. In addition, ad hoc analysis at 90
days showed that patients treated with the EP
NPWT device were twice as likely to not have
healed compared with patients treated with the
MP NPWT device. The difference seen between the
two devices at 30 days was greater than at 90 days
most likely due to diminishing effects of NPWT as a
monotherapy treatment to closure.
Despite randomization, there was a difference in
the baseline median wound size between the two
groups studied, with the EP NPWT group being
larger on average. This was likely due to the rela-
tively small number of patients in each group and
the wide range of wound sizes eligible for enrollment
(1–100 cm2). To adjust for this baseline wound size,
covariate analysis was performed and the difference
in percent wound closure remained significant. This
indicates that wound size does not completely ac-
count for the difference in results observed between
the two types of NPWT. One would expect to see
noninferiority between the MP NPWT-treated and
the EP NPWT-treated subjects in this VLU subset
Table 2. Venous leg ulcers—wound size reduction
V.A.C. Mean (%)
(SD), n = 21
SNaP Mean
(%) (SD), n = 19
Impact of Baseline Wound
Size Difference (p-Value)
p-Valuea (Unadjusted
for Baseline Wound Size)
p-Valuea (Adjusted
for Baseline Wound Size)
4 weeks - 9.87 ( – 106.04) - 35.35 ( – 69.23) 0.1606 0.0039b 0.0346b
8 weeks - 30.20 ( – 116.49) - 47.46 ( – 110.99) 0.0419b 0.0086b 0.0803
12 weeks - 30.20 ( – 118.26) - 56.29 ( – 112.89) 0.0559 0.0002b 0.0079b
16 weeks - 42.00 ( – 119.20) - 57.80 ( – 113.00) 0.0470b 0.0005b 0.0082b
ap-Values generated using Monte Carlo simulation.
bStatistically significant (*p < 0.05).
Table 3. Patients with device-related adverse events
Adverse Event VAC (n = 21) SNaP (n = 19) p-Valuea
Infection 9.5% (2) 5.3% (1) 1.000
Maceration 14.3% (3) 15.8% (3) 1.000
Allergic reaction to dressing 14.3% (3) 5.3% (1) 0.607
Pain 14.3% (3) 5.3% (1) 0.607
Blisters 9.5% (2) 15.8% (3) 0.654
Other 9.5% (2) 10.5% (2) 1.000
aFisher’s exact test.
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given that both systems have been shown to provide
similar NPWT therapy25 with similar clinical out-
comes.16,17 The main weakness of this study is the
relatively small sample size leading to the variability
in baseline wound sizes. The findings require con-
firmation in a study with larger sample size of VLU
patients.
Although it is unclear why there might be differ-
ences in the response of wounds to varying types of
NPWT, a number of factors might be involved. First,
of the two devices used in this comparison, the MP
NPWT System is more compact, lightweight, and
does not require battery power or recharging for
operation. Overall, this increased portability may
enhance patient adherence resulting in more effec-
tive hours per day receiving NPWT therapy. Pre-
vious study results have shown that the MP NPWT
system offers significantly better quality of life ad-
vantages over the EP NPWT system such as less
detrimental impact on daily activities, overall higher
mobility level, improved sleep, reduced noise level,
and better levels of comfort in social situations, in
addition to overall wearability.17 These factors can
significantly affect a patient’s psychological well-be-
ing and may have effects on compliance and overall
outcomes.10,35–38 It also stands to reason that the
compact nature of the MP NPWT device may yield a
relatively higher activity level than the heavier EP
NPWT device resulting in increased calf muscle
pump activation and reduction in venous pressures
in the affected limb.
Second, the two systems use different wound
interface materials, with the MP NPWT device
employing a gauze interface while the EP NPWT
device used a foam interface. Preclinical study
results suggest that gauze dressings may be more
effective for smaller and shallower wounds or in
painful ulcers.14,39,40 VLUs are typically more
superficial than other types of chronic wounds
extending only through the dermis into the sub-
cutaneous tissue. Foam interfaces appear to be
particularly useful to stimulate granulation tis-
sue formation to fill wounds, but the venous ulcer
may require more epithelial migration and cov-
erage rather than wound granulation.
Third, the fact that all MP NPWT dressing
changes were performed by a clinician at a wound
care center may have enabled the MP NPWT-
treated patients to have more consistent care
compared to the EP NPWT-treated patients, whose
dressings were performed at home by visiting
nurses. This may have been particularly important
in the routine application of compression therapy,
which is the primary treatment for the underlying
venous insufficiency.41
Finally, additional design features of the MP
NPWT system may have also played a role. Its
hydrocolloid dressing may protect periwound skin,
reducing maceration or other adverse effects of
NPWT on the periwound area. Overall compati-
bility of the MP NPWT system and compression
therapy may have impacted the healing response of
the VLUs as well. Further study in a larger sample
size may be necessary to evaluate risk factors
contributing to healing in patients with VLUs
treated with NPWT.
INNOVATION
VLUs represent a major challenge in wound
healing. NPWT appears to be an effective method
of treatment for patients with VLUs. Compared to
subjects treated with the EP NPWT system, those
subjects treated with the MP NPWT system expe-
rienced significantly faster wound healing. This
information may be useful in selecting NPWT for
treatment of refractory VLUs. Additional study in
a larger patient cohort would allow identification of
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NPWT¼ negative pressure wound therapy
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SNaP¼ Smart Negative Pressure
V.A.C.¼ Vacuum-Assisted Closure
VLU¼ venous leg ulcer
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